Overview
SoftWave TRT is a medical technology company focused on shockwave therapy to aid tissue healing and regeneration. Its devices emit low‑to‑moderate energy acoustic shocks that are applied to injured or painful areas, stimulating biological responses to speed healing, reduce pain, and improve function. The therapy is used across orthopedics, traumatology, wound care, aesthetics, and urology, and is backed by clinical studies and adoption by major medical centers. What sets SoftWave apart is its governance of a German‑engineered platform with manufacturing partners and a track record of more than 300 published studies, along with international recognition from ISMST and a broad global footprint. The company’s goal is to advance scientific knowledge and provide effective, accessible treatments to improve patients’ quality of life around the world.
Work here?Claim your company
Simplify's take
What believers are saying
- The January 9, 2026 leadership overhaul added Tom Rhoads and Luke Olson.
- The VA contract can accelerate adoption across veterans' pain and wound care clinics.
- SoftWave's May 2026 update says its contract holder status supports government sales expansion.
What critics are saying
- SoftWave is litigating DJO, LLC and Moon Pool, LLC over patent infringement.
- Court records show a July 15, 2026 injunction against Launch Medical and Wolff Clinic.
- Any adverse patent ruling would cripple exclusivity and undermine SoftWave's entire device franchise.
What makes SoftWave TRT unique
- SoftWave TRT sells electrohydraulic shockwave devices, not consumable-focused pain products.
- The VA Federal Supply Schedule contract runs July 15, 2023 through July 14, 2028.
- Its research library and FDA-cleared indications support wound care, pain, and circulation claims.
Help us improve and share your feedback! Did you find this helpful?